null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal debt; Ovid is primarily equity-financed with cash runway from equity raises; leverage ratio near zero, so 20bp rate move has negligible P&L impact.

Low sensitivity; no meaningful floating-rate debt; higher rates increase opportunity cost of cash holdings but don't materially affect operating expenses.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API/CMO manufacturing concentrated in Europe (Lonza/AMRI type CDMOs); 2) active pharmaceutical ingredient sourcing dependent on EU/Indian chemical suppliers.

Revenues are near-zero commercially; no significant international revenue markets yet; currency devaluation exposure is negligible at current stage.

Primarily US-based R&D and operations; no commercial international revenue footprint; clinical trial sites in EU introduce minor FX exposure on trial costs.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CDMO partners for clinical-stage drug manufacturing; switching mid-trial is extremely costly and time-consuming, representing >30% operational input risk.

Biopharmaceutical R&D company; revenue from licensing/collaboration agreements (e.g., Takeda partnership); cloud disruption would cause operational friction but not existential risk.

Secondary model: milestone and royalty receipts from pharma partnerships; cloud termination would disrupt data management but core IP and regulatory filings remain intact.

Limited API coupling risk; uses standard scientific computing and CRO data platforms; switching costs moderate but not business-critical given asset-light data infrastructure.

Low Howey risk; revenue model is pharmaceutical licensing and R&D collaboration, not investment contracts; equity is standard stock, not a token or passive investment scheme.

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA exposure minimal given no consumer-facing product; compliance managed through CRO and site agreements.

Low antitrust risk; operates in rare/orphan disease niches with no dominant market position; no pricing power scrutiny applicable given pre-commercial stage.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based; upfront license fees and event-driven milestones from Takeda and other partners; no recurring subscription revenue.

Licensing milestones and research collaboration payments; future royalties on partnered assets; no direct product sales revenue currently.

No direct product pricing yet; partnership economics set by negotiated milestone structures; pricing stress is absorbed by partner (Takeda), limiting Ovid's direct exposure.

Moderate long-term pricing power if drugs reach orphan-disease market; orphan drug designation supports premium pricing, but dependent on approval outcomes.

Potential 80-90%+ gross margins on royalty/licensing revenues at scale; current gross margins distorted by R&D-heavy cost structure and minimal revenue.

No free-rider problem; IP-protected drug pipeline with no open-access components; collaboration partners contractually bound; churn risk is partner termination of agreements.

Revenue growth is sublinear to headcount; milestone and royalty revenues can scale without proportional headcount increases; lean ~30-50 person organization model.

Near-zero marginal cost for royalty/milestone revenue; incremental clinical investment is lumpy but does not require linear headcount scaling.

Not applicable; Ovid does not operate a franchise network.

At 10x scale (royalty-generating), CAC is effectively zero for royalty streams; partnership deal costs are high upfront but amortize over multi-decade royalty horizons.

No network effects; pharmaceutical R&D is not a network-effect business; value derives from IP exclusivity and clinical data, not user density.

-11.5% Return on Assets (Negative equity)

Moderate-high resilience; orphan disease patients have inelastic treatment demand; R&D funding dependent on capital markets, which are cyclically sensitive.

Large pharmaceutical partners (e.g., Takeda) as licensees; extreme customer concentration with Takeda representing majority of collaboration revenue.

Government grants (NIH/NCATS) and rare disease foundations as secondary funding sources; patient advocacy groups indirectly influence pipeline prioritization.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001636651

OVID